Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Canada Graduate Scholarships- Master’s Program (CGS M)
FY 2022-23
Summary
In 2021, it was estimated that 1.3 million pregnant women were living with HIV, of which an estimated 81% received antiretroviral drugs to prevent mother-to-child transmission. HIV antiretrovirals (ARVs) are a first-line recommendation for pregnant women living with HIV (PWLH) for the reduction of perinatal HIV transmission.
Adverse birth outcomes are frequently observed in HIV-positive pregnancies exposed to ARV’s. Several studies have found ARV use in pregnancy was associated with increased incidences of miscarriage, fetal growth restriction, small for gestational age, and pre-term deliveries.
The proposed EcoHIV mouse model parallels several major characteristics of HIV in humans including virus targeting to lymphocytes and macrophages, susceptibility to ARVs, induction of anti-viral immune responses, and elevation of inflammatory markers. We hypothesize the EcoHIV model can be used to successfully and conveniently investigate the impact of in-utero ARV exposure on maternal health and fetal development.
This will be done through:
Aim 1: Establishing a successful EcoHIV-infected pregnant mouse model - the data from this aim will be used to optimize the timing of mating, initiation of cART, and vertical transmission frequency, so that the model can effectively be used for studying antiretroviral safety/toxicity in pregnancy. This is then immediately followed by Aim 2: Assessing the effect of NNRTI, NRTI, PI, INSTI-based ART on the EcoHIV infected pregnant mouse model.
The results obtained from the proposed studies will serve to improve the quality of life for PWLH and their children, and develop protocols to reduce fetal anomalies associated with ARV use during pregnancy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486155
Name
Ranjbar Michelle M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Canada Graduate Scholarships- Master’s Program (CGS M)
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Birth Outcomes; Antiretroviral Therapy; Drug Safety; Ecohiv; Hiv Antiretroviral Toxicity; Hiv Infected Mice; Maternal And Fetal Health; Mouse Model; Pregnancy
Abstract
In 2021, it was estimated that 1.3 million pregnant women were living with HIV, of which an estimated 81% received antiretroviral drugs to prevent mother-to-child transmission. HIV antiretrovirals (ARVs) are a first-line recommendation for pregnant women living with HIV (PWLH) for the reduction of perinatal HIV transmission.
Adverse birth outcomes are frequently observed in HIV-positive pregnancies exposed to ARV’s. Several studies have found ARV use in pregnancy was associated with increased incidences of miscarriage, fetal growth restriction, small for gestational age, and pre-term deliveries.
The proposed EcoHIV mouse model parallels several major characteristics of HIV in humans including virus targeting to lymphocytes and macrophages, susceptibility to ARVs, induction of anti-viral immune responses, and elevation of inflammatory markers. We hypothesize the EcoHIV model can be used to successfully and conveniently investigate the impact of in-utero ARV exposure on maternal health and fetal development.
This will be done through:
Aim 1: Establishing a successful EcoHIV-infected pregnant mouse model - the data from this aim will be used to optimize the timing of mating, initiation of cART, and vertical transmission frequency, so that the model can effectively be used for studying antiretroviral safety/toxicity in pregnancy. This is then immediately followed by Aim 2: Assessing the effect of NNRTI, NRTI, PI, INSTI-based ART on the EcoHIV infected pregnant mouse model.
The results obtained from the proposed studies will serve to improve the quality of life for PWLH and their children, and develop protocols to reduce fetal anomalies associated with ARV use during pregnancy.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ranjbar, Michelle M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~